Halim N D, Weickert C S, McClintock B W, Hyde T M, Weinberger D R, Kleinman J E, Lipska B K
Clinical Brain Disorders Branch, Intramural Research Program, National Institutes of Mental Health, NIH, Bethesda, MD, USA.
Mol Psychiatry. 2003 Sep;8(9):797-810. doi: 10.1038/sj.mp.4001319.
Dysfunction of the prefrontal cortex in schizophrenia may be associated with abnormalities in synaptic structure and/or function and reflected in altered concentrations of proteins in presynaptic terminals and involved in synaptic plasticity (synaptobrevin/ vesicle-associated membrane protein (VAMP), synaptosomal-associated protein-25 (SNAP-25), syntaxin, synaptophysin and growth-associated protein-43 (GAP-43)). We examined the immunoreactivity of these synapse-associated proteins via quantitative immunoblotting in the prefrontal cortex of patients with schizophrenia (n=18) and in normal controls (n=23). We also tested the stability of these proteins across successive post-mortem intervals in rat brains (at 0, 3, 12, 24, 48, and 70 h). To investigate whether experimental manipulation of prefrontal cortical development in the rat alters prefrontal synaptic protein levels, we lesioned the ventral hippocampus of rats on postnatal day 7 and measured immunoreactivity of presynaptic proteins in the prefrontal cortex on postnatal day 70. VAMP immunoreactivity was lower in the schizophrenic patients by 22% (P<0.03). There were no differences in the immunoreactivity of any other proteins measured in schizophrenic patients as compared to the matched controls. Proteins were fairly stable up to 24 h and thereafter the abundance of most proteins examined was significantly reduced (falling to as low as 20% of baseline levels at 48-70 h). VAMP immunoreactivity was higher in the lesioned rats as compared to sham controls by 22% (P&<0.03). There were no significant differences between the lesioned rats and sham animals in any other presynaptic protein. These data suggest that apparently profound prefrontal cortical dysfunction in schizophrenia, as well as in an animal model of schizophrenia, may exist without gross changes in the abundance of many synaptic proteins but discrete changes in selected presynaptic molecules may be present.
精神分裂症患者前额叶皮质功能障碍可能与突触结构和/或功能异常有关,并反映在突触前终末蛋白质浓度的改变上,且与突触可塑性(突触小泡蛋白/囊泡相关膜蛋白(VAMP)、突触体相关蛋白-25(SNAP-25)、 syntaxin、突触素和生长相关蛋白-43(GAP-43))有关。我们通过定量免疫印迹法检测了精神分裂症患者(n = 18)和正常对照者(n = 23)前额叶皮质中这些突触相关蛋白的免疫反应性。我们还测试了这些蛋白质在大鼠脑连续尸检间隔(0、3、12、24、48和70小时)期间的稳定性。为了研究对大鼠前额叶皮质发育进行实验性操作是否会改变前额叶突触蛋白水平,我们在出生后第7天损伤大鼠的腹侧海马体,并在出生后第70天测量前额叶皮质中突触前蛋白的免疫反应性。精神分裂症患者的VAMP免疫反应性降低了22%(P<0.03)。与匹配的对照组相比,精神分裂症患者中检测的任何其他蛋白质的免疫反应性均无差异。蛋白质在24小时内相当稳定,此后大多数检测蛋白质的丰度显著降低(在48 - 70小时降至基线水平的20%)。与假手术对照组相比,损伤大鼠的VAMP免疫反应性高22%(P<0.03)。损伤大鼠与假手术动物在任何其他突触前蛋白方面均无显著差异。这些数据表明,精神分裂症以及精神分裂症动物模型中明显严重的前额叶皮质功能障碍可能在许多突触蛋白丰度无明显变化的情况下存在,但可能存在某些突触前分子的离散变化。